Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|S0303||SWOG||A Phase III Trial of Modified FOLFOX6 Versus CAPOX; with Bevacizumab (NSC-704865) or Placebo; as First-Line Therapy in Patients with Previously Untreated Advanced Colorectal Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NCCTG-N06C6||NCCTG||A Phase III Randomized Trial of Cryoablation vs. Radiation for the Palliation of Painful Bone Metastases||Adult CIRB - Late Phase Emphasis||Completed|
|NSABP-B-51||NSABP||A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0262||GOG||GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel In Combination With Carboplatin With Or Without Concurrent and Consolidation Bevacizumab (NSC #704865; IND #113912) in the Treatment of Primary Stage II; III OR IV Epithelial Ovarian; Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging To Evaluate Treatment Response in Patients Participating in GOG-0262||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031702||Alliance||A Phase II Study of Ipilimumab, Cabozantinib, and NIvolumab in Rare Genitourinary Cancers (ICONIC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900E||SWOG||A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A041202||Alliance||A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|E3201||ECOG||Intergroup Randomized Phase III Study of Postoperative Irinotecan; 5-Fluorouracil and Leucovorin Vs Oxaliplatin; 5-Fluorouracil and Leucovorin Vs 5-Fluorouracil and Leucovorin For Patients with Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil||Adult CIRB - Late Phase Emphasis||Completed|
|S1203||SWOG||A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0825||RTOG||Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma||Adult CIRB - Late Phase Emphasis||Completed|